Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$1.83 USD
-0.04 (-2.14%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $1.82 -0.01 (-0.55%) 4:48 PM ET
3-Hold of 5 3
D Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
HRTX 1.83 -0.04(-2.14%)
Will HRTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for HRTX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HRTX
Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates
HRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why
Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know
United Therapeutics (UTHR) Completes Enrolment in IPF Study
Other News for HRTX
Heron Therapeutics: Zynrelef Developments Are Unlikely To Provide Relief To Investors
Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics names Brett Fleshman as Chief Business Officer
Heron Therapeutics, Inc., (HRTX) Q2 2024 Earnings Call Transcript
Heron Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation